Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05787587 · ClinicalTrials.gov registry record · Phase 1

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors

A Phase 1 study of Breast Cancer and Prostate Cancer, sponsored by IDEAYA Biosciences.

Recruiting
Registry status
Phase 1
Development phase
216
Enrollment target
20
Study locations

NCT05787587 is a Phase 1 study of Breast Cancer and Prostate Cancer that is actively recruiting participants, run by IDEAYA Biosciences. The registered enrollment target is 216 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05787587, a Phase 1 study of Breast Cancer and Prostate Cancer, is actively recruiting participants, sponsored by IDEAYA Biosciences.

RECRUITING
Registry status
Phase 1
Development phase
216 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.

Conditions Studied

Breast Cancer Prostate Cancer Colorectal Cancer Ovarian Cancer Endometrial Cancer NSCLC Advanced or Metastatic Solid Tumors Head and Neck Cancers Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Interventions

  • DRUG Pembrolizumab
  • DRUG IDE-161

Study Locations (20)

California

  • The Angeles Clinic - Los Angeles
  • Hoag Memorial Hospital - Newport Beach
  • California Pacific Medical Center - San Francisco

New York

  • Roswell Park Comprehensive Cancer Center - Buffalo
  • Columbia University Medical Center - New York
  • Weil Cornell University - New York

Pennsylvania

  • University of Pennsylvania - Philadelphia
  • Sarah Cannon Research Institute - Thomas Jefferson University - Philadelphia

Arizona

  • HonorHealth Research Institute - Phoenix

Colorado

  • Sarah Cannon Research Institute - Denver

Connecticut

  • Yale University - New Haven

Florida

  • Orlando Health - Orlando

Georgia

  • Emory University - Atlanta

Trial Details

FieldValue
Enrollment Target 216 participants
Start Date 2023-04-18
Est. Completion 2027-05
Phase Phase 1

Sponsor

IDEAYA Biosciences

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05787587

The ClinicalTrials.gov registry entry for NCT05787587 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (92% lower). The listed sponsor is IDEAYA Biosciences, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT05787587 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05787587 about?

NCT05787587 is a clinical study titled "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors". The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.

What is the current status of trial NCT05787587?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 216 participants. The study started on 2023-04-18. Estimated completion is 2027-05.

What conditions does trial NCT05787587 study?

This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Endometrial Cancer.

What interventions are being tested in trial NCT05787587?

The interventions under investigation include: Pembrolizumab (DRUG), IDE-161 (DRUG).

Who is sponsoring clinical trial NCT05787587?

This trial is sponsored by IDEAYA Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05787587 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.